Physician profile
Aaron A Sookhoo
NPI 1871975623
$742,319.67
in general payments reported to CMS, 2019-2025
34 companies · $358K in 2025
The $358K reported for 2025 was more than what 99% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $5,425 · 2022: $15K · 2023: $147K · 2024: $217K · 2025: $358K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $432K · Consulting Fee: $128K · Travel and Lodging: $122K · Food and Beverage: $40K · Education: $578 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $432,090.90 |
| Consulting Fee | $127,506.77 |
| Travel and Lodging | $121,749.59 |
| Food and Beverage | $40,103.37 |
| Education | $578.21 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $122.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $330,904.17 | 2021-2025 | Tremfya, Simponi Aria, Remicade |
| Arcutis Biotherapeutics, INC. | $131,829.73 | 2023-2025 | Zoryve |
| Pfizer INC. | $71,115.30 | 2021-2025 | |
| Ucb, INC. | $43,217.15 | 2021-2025 | Bimzelx |
| Abbvie INC. | $40,265.56 | 2021-2025 | |
| Galderma Laboratories, L.P. | $35,837.73 | 2021-2025 | Nemluvio, Epsolay, Aklief |
| Botanix Sb INC | $30,519.69 | 2025 | Sofdra |
| Janssen Scientific Affairs, LLC | $12,315.37 | 2021-2024 | Tremfya |
| Verrica Pharmaceuticals INC. | $12,298.54 | 2023-2025 | Ycanth |
| Incyte Corporation | $6,757.41 | 2021-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $5,257.74 | 2022-2025 | Sotyktu |
| Genzyme Corporation | $4,402.63 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $3,715.75 | 2021-2025 | Dupixent, Libtayo |
| Journey Medical Corporation | $3,275.89 | 2021-2025 | |
| Leo Pharma INC. | $2,585.20 | 2021-2025 | Adbry, Anzupgo |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $1,830.65 | 2021-2025 | Winlevi, Absorica Ld, Ilumya |
| Novartis Pharmaceuticals Corporation | $1,744.96 | 2021-2025 | |
| Lilly USA, LLC | $998.56 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Eli Lilly and Company | $844.71 | 2022-2024 | Olumiant |
| Amgen INC. | $505.52 | 2021-2025 | Otezla, Otezla |
| Dermavant Sciences, INC. | $384.29 | 2023-2024 | Vtama |
| Kowa Pharmaceuticals America, INC. | $350.00 | 2025 | Zoryve |
| Mayne Pharma Commercial LLC | $294.86 | 2021-2025 | |
| Kerecis Limited | $226.45 | 2023-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Sanofi-Aventis U.S. LLC | $178.99 | 2022-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $130.81 | 2021-2024 | Jublia, Duobrii, Siliq |
| Allergan, INC. | $122.70 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.34 | 2022-2025 | Spevigo |
| Almirall LLC | $93.11 | 2021-2025 | Seysara |
| Organon LLC | $60.02 | 2025 | Vtama |
| Sebela Pharmaceuticals INC. | $46.74 | 2022-2023 | Naftin, Pramosone |
| Helsinn Therapeutics (U.S.), INC. | $38.71 | 2022-2023 | Valchlor |
| Kyowa Kirin, INC. | $28.02 | 2025 | |
| Lnhc, INC | $23.37 | 2025 | Zelsuvmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Sookhoo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.